atopic dermatitis

[Connect Biopharma Holdings Limited] Connect Biopharma Holdings Limited reported positive topline results from the global Phase II clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.

[Journal of the American Academy of Dermatology] The authors propose a novel framework to assess atopic dermatitis (AD) based on literature review and clinical experience. Rather than placing focus on any single specific aspect of AD, DESCRIBE-AD allows for a comprehensive approach to the assessment and clinical management of AD.

[Science Translational Medicine] Researchers found that the cytokine oncostatin M was highly up-regulated in psoriasis, atopic dermatitis, and cutaneous T cell lymphoma, diseases associated with chronic itch.

[PLoS One] Investigators established a model for interleukin 1β (IL-1β)-induced dermatitis and investigated mitogen-activated protein kinase signaling pathways in IL-1β-induced interleukin 8 (IL-8) expression.

[Cochrane Database of Systematic Reviews] Investigators assess the effects of phototherapy for treating atopic eczema, a treatment used when topical treatments, such as corticosteroids, are insufficient or poorly tolerated.

[ASLAN Pharmaceuticals] ASLAN Pharmaceuticals announced a collaboration with renowned inflammatory skin disease expert Dr. Emma Guttman-Yassky to conduct research that will continue throughout ASLAN’s Phase IIb program to identify and characterize the effects of ASLAN004 on disease-associated skin and serum-biomarkers in adults with moderate-to-severe atopic dermatitis.